<DOC>
	<DOCNO>NCT01511510</DOCNO>
	<brief_summary>This study aim assess safety , tolerability , pharmacokinetics PF-04958242 number ascend dos administer daily 14 day healthy volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Pharmacokinetics Repeated Doses PF-04958242 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy male and/or female subject nonchild bear potential Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease History seizures condition risk seizure Pregnant nursing female , female child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>PF-04958242</keyword>
	<keyword>multiple dose</keyword>
	<keyword>safety</keyword>
	<keyword>schizophrenia</keyword>
</DOC>